Tyrosine Kinases as Targets for Cancer Therapy

N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Benzamides
  • Drug Resistance, Neoplasm / genetics
  • Gene Expression Regulation, Neoplastic
  • Hematologic Neoplasms / drug therapy
  • Humans
  • Imatinib Mesylate
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Pyrimidines / therapeutic use
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / genetics
  • fms-Like Tyrosine Kinase 3

Substances

  • Antibodies, Monoclonal
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Pyrimidines
  • Imatinib Mesylate
  • FLT3 protein, human
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases
  • fms-Like Tyrosine Kinase 3